Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.
The post discusses a successful hair loss treatment involving a hair transplant, finasteride, and minoxidil. The user underwent a 2000 graft hair transplant at the hairline in a clinic in Sweden.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
The user has been using Dutasteride for five years and noticed slow thinning on the frontal hairline. They tried Fluridil as an additional treatment, which resulted in noticeable hairline thickening after two months.
A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.
Hair thickness can fluctuate while on finasteride, possibly due to product overuse or other factors like health or hormones. The user experienced a significant thinning in November 2025 but noticed improvement since then.
A 21-year-old male with advanced hair loss (NW7) started using finasteride and minoxidil 10 months ago but hasn't seen much progress. He is pre-diabetic with stage 1 hypertension and is seeking insights on whether treating these conditions could improve hair regrowth.
Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.
A user shared their 3.5-4 month progress using Topical Minoxidil, Oral Finasteride, Keto 1%, and Dermastamp, reporting positive results despite some shedding and flaking. Replies praised the progress and inquired about the treatment routine and temple condition.
OP increased their dutasteride dosage from 0.1mg to 0.5mg and initially saw regrowth but is now experiencing significant hair shedding. They are concerned if this shedding is normal or if they should revert to the lower dosage.
A user with androgenetic alopecia is using 8 ml of 1.4% topical spironolactone solution daily but is unsure if this amount is excessive, as 2 ml is more typical. They seek advice on the appropriate amount to apply.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
The conversation discusses hair loss treatments for a woman experiencing androgenetic alopecia and seborrheic dermatitis, with suggestions including low-dose oral minoxidil, dutasteride, and hormone replacement therapy. The user is seeking advice due to intolerance to spironolactone and topical minoxidil, and concerns about low testosterone and DHT levels.
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.
The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
Small hairs around the hairline may regrow with continued use of minoxidil, finasteride, and ketoconazole. The user is hopeful about hairline improvement.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
The user improved hair density from 45% to 70% using dutasteride and minoxidil, but still uses hair fibers for a fuller look. They added a topical mix of minoxidil, finasteride, and bimatoprost, but doubt further significant improvement.
Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.
Switching from Arimidex to Raloxifene worsened hair loss despite using Dutasteride. The user added oral Minoxidil, dermastamping, and RU58841 to their regimen to address the issue.
The user had four DHI hair transplants from 2021 to 2025 and is concerned about the lack of hair thickening despite using treatments like finasteride and minoxidil. They are seeking advice on why these efforts aren't working.
The user is experiencing diffuse thinning after 10-11 months on oral finasteride and is concerned about whether this is a normal shedding phase. They have been using topical finasteride and minoxidil for over a year.
The user has been using a daily topical spray of finasteride and minoxidil, along with occasional microneedling, to address hair loss since August 2023, and is considering switching to oral medication for convenience and cost reasons. Despite progress, they are exploring options like increasing microneedling frequency or potentially undergoing a hair transplant to address a stubborn spot.
Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.
The user switched from finasteride to dutasteride after experiencing significant hair shedding and thinning. Recently, they noticed their hair appearing thicker and their hairline improving, questioning if the switch was necessary and if the improvement is due to growth or regrowth.